ACTION REQUEST

Subject: Fourth Amendment to License Agreement between the University of Michigan and NanoBio Corporation

Action Requested: Approval of Amendment

Preamble:

A statutory conflict of interest situation was identified by the Office of Technology Transfer while reviewing the technology transfer agreement that then triggered a review by the Medical School Conflict of Interest Board. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by this Board and agreed to by the parties involved in this plan.

This proposed amendment ("Agreement") falls under the State of Michigan Conflict of Interest Statute because Professor James R. Baker, Jr. is both an employee of the University of Michigan ("University") and an owner, director and officer of NanoBio Corporation ("NanoBio"). The law permits such an Agreement provided it is disclosed to the executive officers and approved in advance by a 2/3 vote of the Regents of the University of Michigan.

Background:

Dr. Baker, the Director of the Michigan Nanotechnology Institute for Medicine and Biological Sciences and a Professor in the Departments of Internal Medicine and Biomedical Engineering, is an owner, director and officer of a for-profit company called NanoBio (the "Company"). The University and the Company entered into the original license in August 2000 when the Company was formed to commercialize therapeutic uses of emulsion-based compositions. This license has been amended three times to add additional technologies from the University. The Company now wishes to add the following technology from the University into the existing license:

UM File No. 4731, entitled: "Nanoemulsion Vaccines" (inventors James R. Baker, Jr., Susan Ciotti and Tarek Hamouda)

Parties to the Agreement:

The Regents of the University of Michigan and NanoBio Corporation.

Agreement Terms:

Agreement terms include giving the Company an exclusive license with the right to grant sublicenses. The Company will pay a royalty on sales and reimburse patent costs. The University will retain ownership of the licensed technology and may
continue to further develop it and use it internally. No use of University services or facilities, nor any assignment of University employees, is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technologies. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Pecuniary Interest:

The pecuniary interest of Dr. Baker arises from his ownership interest in NanoBio.

Net Effect:

The Office of Technology Transfer has negotiated and finalized the terms of an amendment to the existing worldwide exclusive license agreement for patents related to UM OTT File No. 4731 for all fields.

NanoBio will obtain use and commercialization rights to the above listed University technology.

Recommendations:

This matter has been reviewed and approved by the Medical School Conflict of Interest Board. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the fourth Amendment between the University and NanoBio Corporation.

Respectfully submitted,

Stephen R. Forrest
Vice President for Research

July 2011